NCT05911724View on ClinicalTrials.gov

Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.

CompletedOBSERVATIONAL
Enrollment

180

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

September 20, 2024

Study Completion Date

September 30, 2024

Conditions
Stable AnginaHeart Failure
Interventions
OTHER

Group I Healthy

Healthy Subjects

DRUG

CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study

Group II: Stable Angina Patients

DRUG

HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study

Group III: Heart Failure Patients

Trial Locations (1)

31527

Tanta University Hospital, Tanta

All Listed Sponsors
collaborator

Tanta University

OTHER

lead

Damanhour University

OTHER